Data from the same IFEBP survey indicates that GLP-1 drug costs as a proportion of total annual claims are increasing, with GLP-1 expenses accounting for an average of 8.9% of total annual claims for US employers, up from 6.9% in the 2023 survey
Diagnostic tests may include an upper endoscopy, a 24-hour ambulatory acid probe test, esophageal motility testing, and X-rays of the upper digestive system
Other Important Considerations When Using GLP-1 Therapy By design, GLP-1 medications alter appetite regulation, gastric emptying, and satiety signaling
Can fake reta contain the wrong dose
Rubino, D., et al., Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: the STEP 4 randomized clinical trial